 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

---
- Alan Brochstein shares his thoughts on uplisting, the ETF MSOS, volume and valuation
  issues and confronting the California cannabis landscape.


Alan Brochstein: The Longer Legislation Takes, The Better For Cannabis Companies (Podcast)

---
- Cannabidiol (CBD) is one of the major cannabinoids found in cannabis; CV Sciences
  operates in the space via consumer products and drug development.


CV Sciences CEO Joseph Dowling - Mainstreaming Cannabinoids (Video)

---
- Jazz Pharmaceuticals (JAZZ) estimates ~18.1% of additional revenue in 2021 as a
  result of the acquisition of GW Pharmaceuticals (GWPH), the updated financial guidance
  issuedby the...


Jazz updates 2021 financial guidance to reflect impact of GW Pharma acquisition

---
- GW Pharmaceuticals plc (NASDAQ:GWPH) has been assigned a consensus rating of Hold
  from the sixteen research firms that are currently covering the company, MarketBeat
  Ratings reports. One investment analyst has rated the stock with a sell rating,
  ten have given a hold rating and four ...


GW Pharmaceuticals plc (NASDAQ:GWPH) Receives $213.11 Consensus PT from Analysts

---
- Monteverde & Associates PC Filed A Class Action Lawsuit On Behalf Of Shareholders
  Of GW Pharmaceuticals, PLC In The Southern District Of California Monteverde & Associates
  PC Filed A Class Action Lawsuit On Behalf Of Shareholders Of GW Pharmaceuticals,
  PLC In The Southern District...


Monteverde & Associates PC Filed A Class Action Lawsuit On Behalf Of Shareholders Of GW Pharmaceuticals, PLC In The Southern District Of California

---
- Davy Global Fund Management Ltd raised its stake in shares of GW Pharmaceuticals
  plc (NASDAQ:GWPH) by 285.6% in the first quarter, according to its most recent 13F
  filing with the Securities  Exchange Commission. The firm owned 36,750 shares of
  the biopharmaceutical companys stock after ...


GW Pharmaceuticals plc (NASDAQ:GWPH) Shares Bought by Davy Global Fund Management Ltd

---
- Alberta Investment Management Corp bought a new stake in GW Pharmaceuticals plc
  (NASDAQ:GWPH) during the first quarter, according to the company in its most recent
  13F filing with the SEC. The institutional investor bought 18,400 shares of the
  biopharmaceutical companys stock, valued at ...


Alberta Investment Management Corp Takes $3.99 Million Position in GW Pharmaceuticals plc (NASDAQ:GWPH)

---
- US Bancorp DE cut its holdings in shares of GW Pharmaceuticals plc (NASDAQ:GWPH)
  by 95.3% in the 1st quarter, Holdings Channel reports. The fund owned 780 shares
  of the biopharmaceutical companys stock after selling 15,750 shares during the period.
  US Bancorp DEs holdings in GW Pharmaceuticals were ...


GW Pharmaceuticals plc (NASDAQ:GWPH) Shares Sold by US Bancorp DE

---
- Commonwealth Equity Services LLC lessened its stake in shares of GW Pharmaceuticals
  plc (NASDAQ:GWPH) by 38.7% in the first quarter, according to its most recent filing
  with the Securities  Exchange Commission. The institutional investor owned 22,517
  shares of the biopharmaceutical company&#...


Commonwealth Equity Services LLC Sells 14,230 Shares of GW Pharmaceuticals plc (NASDAQ:GWPH)

---
- Harvest Management LLC acquired a new position in shares of GW Pharmaceuticals plc
  (NASDAQ:GWPH) during the 1st quarter, according to the company in its most recent
  13F filing with the Securities  Exchange Commission. The firm acquired 44,100 shares
  of the biopharmaceutical companys ...


Harvest Management LLC Buys Shares of 44,100 GW Pharmaceuticals plc (NASDAQ:GWPH)

GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.

Watchers	14,083
52-Wk Low	$87.07
52-Wk High	$219.57

Market Cap	$6.9B
52-Wk High	$219.57
52-Wk Low	$87.07

GWPH GW Pharmaceuticals plc

About

Feed

News

Fundamentals